Laleman Pharma SRL
0.1 FTELaleman Pharma reported total assets of €1.43m at the end of the 2025 financial year (annual accounts filed with the NBB on 08 Jun 2026), with 0.1 full-time equivalent.
The score of Laleman Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Laleman Pharma's annual accounts
| 2025 | |
|---|---|
| Net result | −37,832 € |
| Equity | 212,168 € |
| Cash | 122,538 € |
| EBITDA | 217,011 € |
| Total assets | €1.43m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jun 2026
Laleman Pharma's financial analysis
- Solvency14.8%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Laleman Pharma
Laleman Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1010.156.713
- VAT number
- BE1010156713
- Peppol
- Registered · 0208:1010156713 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 07 Jun 2024
- Registered office
- 8600 Diksmuide
- Size
- Micro · 0.1 FTE
- Latest accounts
- 2025 · filed on 08 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Laleman Pharma (SRL) has been based in Diksmuide since 2024, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 37,832 € and equity of 212,168 €; its revenue is not published. With 0.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 14.8%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Laleman Pharma
Companies in the same business, of comparable size and area, outside its group.
- Apotheek Mees Sint-Truiden Retail sale of pharmaceutical products Sint-Truiden · balance sheet €1.43m
- Duopharm Retail sale of pharmaceutical products Lebbeke · balance sheet €1.43m
- Natessence Retail sale of pharmaceutical products Écaussinnes · balance sheet €1.43m
- Romarix Retail sale of pharmaceutical products Liedekerke · balance sheet €1.43m
- Pharmacie Jonckheere Retail sale of pharmaceutical products Tubize · balance sheet €1.43m
- Dynamic Pharma Retail sale of pharmaceutical products Arlon · balance sheet €1.43m
- Sogipharma Retail sale of pharmaceutical products Wavre · balance sheet €1.43m
- Apoteek Piqueur Retail sale of pharmaceutical products Kapellen · balance sheet €1.42m
Frequently asked questions about Laleman Pharma
What is the revenue of Laleman Pharma?
Laleman Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Laleman Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE1010156713 for Laleman Pharma, if the company is VAT-registered. Its company number (CBE) is 1010.156.713.
Where is the registered office of Laleman Pharma?
According to the CBE register, the registered office of Laleman Pharma is in 8600 Diksmuide.
What is the equity of Laleman Pharma?
At the close of the 2025 financial year, the equity of Laleman Pharma amounts to 212,168 €, a solvency of 14.8% of total assets.
How many people work at Laleman Pharma?
0.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Laleman Pharma?
The register lists 1 active mandates at Laleman Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Laleman Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →